SSC
GSK icon

Syverson Strege & Co’s GSK GSK Stock Holding History

Syverson Strege & Co’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3,847
Closed -$212K – 188
2026
Q1 		$212K Buy
+3,847
New +$208K 0.05% 158
2023
Q2 		– Sell
-327
Closed -$11.6K – 294
2023
Q1 		$11.6K Buy
+327
New +$11.4K 0.01% 236

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Syverson Strege & Co's GSK Position: Q2 2026 in Review

Syverson Strege & Co sold out of GSK (GSK) in Q2 2026, closing a stake of 3,847 shares — an estimated $212K sold.

Syverson Strege & Co first reported a position in GSK in Q1 2023 and held it in 2 quarters. The position peaked at $212K in Q1 2026. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Syverson Strege & Co reported no remaining GSK position as of Q2 2026 after selling out during the quarter.
  • Syverson Strege & Co sold 3,847 GSK shares in Q2 2026, an estimated $212K.
  • Syverson Strege & Co first reported a position in GSK in Q1 2023 and held it in 2 quarters.
  • Syverson Strege & Co's GSK position peaked at $212K in Q1 2026.
  • 1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Syverson Strege & Co's 13F filing for Q2 2026, filed 6 Aug 2026.